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FI identified different but overlapping participants as frail 
compared with the FP; 62.5 % of frail participants accord-
ing to FI were also frail according to the FP.
Conclusions Prevalence of frailty among young and 
elderly ESRD patients is high; being female and having 
more comorbidity was associated with frailty. Use of a 
broader definition of frailty, like the FI, gives a higher esti-
mation of prevalence among ESRD patients compared with 
a physical frailty assessment.
Keywords Elderly · End-stage renal disease · Frailty · 
Frailty index · Frailty phenotype
Introduction
With population aging and improved medical care, there 
is an increasing number of elderly patients with end-stage 
renal disease (ESRD) who become dialysis dependent 
[1, 2]. The prognosis of some of these older patients with 
ESRD after initiating dialysis is poor; mortality is high and 
they are at high risk of functional decline [3]. Recently, 
the concept of frailty, the state of low homeostatic reserve 
leading to a high vulnerability for sudden adverse health 
changes, emerged as a possible good predictor of progno-
sis in the ESRD population [4]. Frail patients undergoing 
hemodialysis had a 2.6 times higher risk of mortality and 
1.4 times higher risk of hospitalization, independent of age, 
gender, comorbidity and disability, compared with patients 
who were not frail [4].
However, there is no clear consensus about the exact def-
inition of frailty [5], and multiple frailty assessment instru-
ments are being implemented to identify frail patients [6]. 
To estimate the prevalence of frailty in databases of ESRD 
populations, researchers used different modifications for 
Abstract 
Purpose Prognosis of the increasing number of elderly 
patients with end-stage renal disease (ESRD) is poor with 
high risk of functional decline and mortality. Frailty seems 
to be a good predictor for those patients that will not ben-
efit from dialysis. Varying prevalences between populations 
are probably related to the instrument used. The aim of 
this study was to measure the prevalence of frailty among 
ESRD patients with two different validated instruments.
Methods This cross-sectional study was conducted among 
patients, aged ≥18 years, receiving hemodialysis, peri-
toneal dialysis and pre-dialysis care between September 
2013 and December 2013 in a single dialysis center in 
Apeldoorn, the Netherlands. Frailty was measured with the 
frailty index (FI) and frailty phenotype (FP).
Results Prevalence of frailty by the FI was 36.8 % among 
95 participants with ESRD (age: 65.2 years, SD ± 12.0). 
Frailty prevalence among participants aged ≥65 and 
<65 years was 43.6 and 27.5 %, respectively. Female sex 
[odds ratio (OR) 3.3, 95 % confidence interval (CI) 1.3–
8.0] and a Charlson comorbidity index score of ≥5 (OR 
2.6, 95 % CI 1.0–6.6) were associated with frailty. The 
Electronic supplementary material The online version of this 
article (doi:10.1007/s11255-016-1306-z) contains supplementary 
material, which is available to authorized users.
 * Barbara C. van Munster 
 b.van.munster@gelre.nl
1 Department of Geriatrics, Gelre Hospitals, Apeldoorn,  
The Netherlands
2 Division of Nephrology, Department of Medicine, Gelre 
Hospitals, Apeldoorn, The Netherlands
3 Department of Medicine, University Medical Center 
Groningen, Groningen, The Netherlands
1358 Int Urol Nephrol (2016) 48:1357–1362
1 3
measurement of the criteria of the frailty phenotype model 
[7]. These modifications, besides possible differences in 
study populations, have led to diverse results; prevalences 
varied from 24 % (n = 188) to more than two-third of an 
ESRD population (n = 2275) [8–10].
Frailty, measured by the original criteria of the frailty 
phenotype in a hemodialysis population, was found in all 
ages with an overall prevalence of 42 % [4]. Compared to 
the prevalence of 7 % in a community-dwelling population 
of ≥65-year elderly [7], it is clear that, although varying 
prevalences are found, prevalence of frailty in the ESRD 
population is high.
Therefore, given the large differences of frailty preva-
lence, it is important to identify whether disagreement in 
frailty measurements plays a role. The aim of this study 
is to establish the prevalence of frailty in ESRD patients 
measured with two validated assessment instruments: the 
Frailty Index [11] (FI) and the Frailty Phenotype [7] (FP) 
in one population and to determine whether the risk factors 
for frailty from the literature correspond to the risk factors 
in an ESRD population.
Subjects and methods
Study population
This cross-sectional study was conducted in a single dialy-
sis center in Gelre Hospitals in Apeldoorn, the Netherlands, 
from September 2013 till December 2013 in patients aged 
18 years and above. Patients receiving chronic hemodialy-
sis, chronic peritoneal dialysis and patients in pre-dialysis 
care were asked to participate. Pre-dialysis care group con-
sists of patients with an estimated glomerular filtration rate 
(eGFR) of <20 ml/min/1.73 m2 but did not yet need renal 
replacement therapy and those patients who are expected to 
be renal replacement therapy dependent quickly, due to fast 
decline of kidney function. The study was reviewed by the 
Medical Ethics Committee (METC) of the Academic Med-
ical Center Amsterdam (Reference Number W13_164 # 
13.17.0209). Written informed consent was obtained from 
participants.
Data collection
At enrollment, trained research staff collected medical 
information from the medical charts, including diagnosed 
comorbidities according to the Charlson comorbidity index 
[12]. eGFR was calculated using the 4-variable Modifi-
cation of Diet in Renal Disease (MDRD) study formula 
[13]. Participants were asked to complete a question-
naire and performed a set of function tests supervised by 
trained research staff (Table S1, online-only). Maximal grip 
strength (average of three measurements) was measured 
in the dominant hand with a type 5030J1 Jamar hydrau-
lic dynamometer. Walking speed (normal and rapid pace) 
was measured as the fastest time of two measurements [7, 
14]. Unrecordable grip strength and inability to walk were 
scored as positive items on both frailty instruments.
Frailty
Frailty was established according to the FI [11] and the 
FP [7]. We used 38 variables and cutoff points as used by 
Searle et al. [14], consisting of physical, psychological, 
social and cognitive items, and documented comorbidity, 
excluding shoulder strength and peak flow measurement 
(Table S1, online-only). The FI was the total deficits as a 
proportion of those counted. The FI was graded in three cat-
egories equivalent to the FP. A FI of ≤0.08 was considered 
as non-frail, a FI of >0.08 and <0.25 as pre-frail and a FI 
of ≥0.25 as frail [15]. The five components of the FP were 
measured: weight loss, exhaustion, weakness, slow walking 
speed and physical activity (Table S1, online-only).
Statistical analysis
Descriptive statistics were given for all baseline demo-
graphic and clinical data. Baseline characteristics were 
compared among frail and non-frail patients (according to 
dichotomized FI). Normally distributed, non-normally dis-
tributed continuous variables and nominal variables were 
tested with a Student’s T test, Mann–Whitney U test or 
Chi-square test, respectively. All patient characteristics var-
iables with p value of <0.10 or associated with frailty based 
on the existing literature [5] were included in a multivari-
able logistic regression analysis with the dichotomized FI 
as outcome. Participants were excluded from analysis of an 
instrument if they had missing values for more than 20 % 
per instrument [16]. The statistical significance level was 
set to 0.05. All analyses were performed using Statistical 
Package for Social Sciences (SPSS) software version 20.
Results
Study population
Of a total of 144 patients, 95 (66 %) participated in this 
study. Individuals in the included and non-responders 
group were similar with respect to age, treatment modality 
and comorbidity index. In the included group, there was a 
lower proportion of females compared to the non-respond-
ers group (43 vs. 68 %; p = .004). The mean age of the 
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95 participants was 65.2 years [Standard Deviation (SD) 
±12.0], range 27 to 88 years. Forty-two participants (44 %) 
were undergoing hemodialysis, 14 (15 %) were undergo-
ing peritoneal dialysis, and 39 (41 %) were receiving pre-
dialysis care.
Frailty
Of the total study population, 36.8 % were considered 
frail by the FI. Frailty prevalence was 43.6 % in partici-
pants of 65 years and above and was 27.5 % in the younger 
group. Women were more likely to be frail compared to 
men (51 % of female vs. 26 % of male; p = .01) (Table 1). 
No difference was found in age between frail (mean 66.6, 
SD ± 13.5; p = .39) and non-frail (mean 64.4, SD ± 11.1) 
individuals; correction for gender or treatment modality 
did not alter this result. Frail participants had a (one point) 
higher Charlson comorbidity index score (median: 4, IQR 
3–6), compared to non-frail participants (median: 3, IQR 
2–5; p = .019). Treatment modality did not differ between 
the frail and non-frail participants.
Predictors of frailty
Age was not associated with frailty [odds ratio (OR) 2.0, 
95 % CI 0.9–4.9] (Table 2). In the multivariable analy-
sis, female sex (OR 3.3, 95 % CI 1.3–8.0) and a Charlson 
comorbidity index score of ≥5 (OR 2.6, 95 % CI 1.0–6.6) 
were associated with frailty (Table 2).
Frailty assessment
A frailty status was established for all participants accord-
ing to the frailty index, however, in seven of the 95 par-
ticipants (7.4 %); no frailty status according to the frailty 
phenotype could be established because of >20 % missing 
data.
Prevalence of frailty in this population according to 
the FI was 36.8 %, compared with a prevalence of 27.3 % 
according to the FP. Sixty-four of the 88 participants 
(73 %) were categorized in the same phenotype category 
(Table 3). Different, but an equal number of participants 
[49 (56 %)] were found pre-frail by the FI and FP. Twenty 
Table 1  Patient characteristics: 
frailty status, according to 
frailty index [11]
Data are presented as: number (%), mean (±SD: standard deviation) or median [25–75 % IQR interquartile 
range]
HD hemodialysis, PD peritoneal dialysis, eGFR estimated glomerular filtration rate, MMSE mini mental 
state examination. Conversion factors for units: serum albumin in g/dL–g/L, ×10; serum hemoglobin in g/
dL–mmol/L, ×0.6206; urea nitrogen in mg/dL–mmol/L, ×0.357
Characteristic Non-frail (n = 60) Frail (n = 35) p value
Female (%) 20 (33.3) 21 (60.0) .01
Age (years) 64.4 (±11.1) 66.6 (±13.5) .39
Race, Caucasian (%) 58 (96.7) 33 (94.3) .42
Treatment modality (%)
 HD 25 (41.7) 17 (48.6) .80
 PD 9 (14.5) 5 (15.2)
 Pre-dialysis 26 (43.3) 13 (37.1)
Body mass index 27.1 [24.0–29.8] 27.0 [25.0–29.4] .81
Laboratory
 eGFR (mL/min/1.73 m2)
(non-dialysis, n = 39)
14.0 [13.0–16.0] 16.0 [13.5–20.5] .10
 Albumin (g/dL) 3.49 (±.36) 3.33 (±.53) .10
 Hemoglobin (g/dL) 11.47 (±1.21) 10.94 (±1.55) .07
 Urea nitrogen (mg/dL) 61.64 [50.40–69.44] 52.23 [39.87–74.69] .12
Time on dialysis, months (n = 56) 14.0 [8.8–43.3] 8.0 [4.5–18.8] .06
 No dialysis (%) 26 (43.3) 13 (37.1) .21
 <12 months 14 (23.3) 14 (40.0)
 ≥12 months 20 (33.3) 8 (22.9)
MMSE (n = 87) 28.5 [27.0–29.0] 27.0 [26.0–29.0] .15
Number of hospitalization last year 1 [0–2] 1 [0–3] .45
Number of medication 9.0 [8.0–13.8] 12.0 [10.0–14.0] .03
Comorbidity Charlson index score 3 [2–5] 4 [3–6] .02
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(23 %) pre-frail and frail participants according to the FI 
were categorized by the FP in the lower non-frail and pre-
frail category.
Discussion
In this cross-sectional study of adults undergoing hemo-
dialysis, peritoneal dialysis or pre-dialysis care, the prev-
alence of frailty was 36.8 %. Being a female and/or hav-
ing more comorbidity was associated with frailty, whereas 
older age was not associated. The frailty index has a lower 
cutoff point for the definition of frailty as more patients 
were identified as frail, in comparison with the frailty phe-
notype in this dialysis population.
To our knowledge, this is the first study that measured 
a frailty index in a ESRD population. The prevalence of 
frailty in this population is much higher than the preva-
lence in community-dwelling elderly [15]. Our findings of 
a higher prevalence are consistent with findings of studies 
where frailty was assessed according to the frailty phe-
notype [4, 8–10]. Several studies used approximations or 
substitutions for several items of the frailty phenotype. 
The only study that used the exact same measurements to 
measure the frailty phenotype developed by Fried et al. 
found a slightly higher estimated prevalence of 41.8 % 
among hemodialysis patients, compared with the current 
study [4]. A possible explanation for this difference could 
be that our study population consisted of an almost entirely 
Caucasian population versus an almost entirely African-
American population, as frailty is more common among 
African-American individuals [7]. The frailty index prev-
alence estimate was 1.4 times higher than the prevalence 
estimated by the frailty phenotype, which is in concordance 
with results found in the general population [15, 17–19]. 
Studies with large study samples of community-dwelling 
adults proposed that these two frailty models capture dif-
ferent but overlapping groups of older adults and that they 
cover different sides of the spectrum of frailty [20, 21]. 
In the community-dwelling population, the frailty index 
defines risk of adverse outcomes, including mortality, more 
precisely than the frailty phenotype does [18, 19]. Thus, the 
FI may be a promising risk indicator in the chronic care of 
pre-dialysis and dialysis population, but further prospec-
tive research with the frailty index in comparison with the 
more traditional vascular risk factors for adverse outcomes 
should be done in these populations.
In the current study population, age was not associated 
with frailty. Frailty is not only prevalent among patients 
aged above 65 years; more than a quarter of young or mid-
dle-aged participants were also identified to be frail. This 
emphasizes the view that ESRD as a chronic condition, 
through proposed mediators of accelerated decline in func-
tioning, such as inflammation, oxidative stress and endo-
crinopathies could lead to frailty [22]. Similar to previous 
studies, female participants were more likely to be frail [17, 
22–24]. The exact mechanism for this gender difference 
is unknown, but possible explanations could be a lower 
lean body mass and muscle strength in women leading to 
sarcopenia and frailty or the development of more frailty 
characteristics due to a longer life expectancy of women 
[5, 7, 17]. The association of a high Charlson comorbidity 
Table 2  Regression analysis of 
variables associated with frailty
Variable Univariate Multivariate
OR (95 % CI) p value OR (95 % CI) p value
Age (≥65 years) 2.0 (0.9–4.9) .11
Female sex 3.0 (1.3–7.1) .01 3.3 (1.3–8.0) .009
Hemoglobin (g/dL) 0.6 (0.4–1.1) .08
Albumin (g/dL) 0.9 (0.8–1.0) .07
Time on dialysis
 No dialysis 1 [reference]
 <12.5 months 2.0 (0.7–5.4) .17
 ≥12.5 months 0.8 (0.3–2.3) .68
Comorbidity Charlson index score ≥5 2.3 (1.0–5.6) .06 2.6 (1.0–6.6) .04
Table 3  Comparison of frailty assessment instruments









 Non-frail (n = 15) 7 8 0
 Pre-frail (n = 49) 0 37 12
 Frail (n = 24) 0 4 20
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index score with frailty is consistent with the view on the 
development of frailty, as multiple stresses, e.g., multi-
ple chronic diseases, could lead to decline in homeostatic 
reserve. Previous research showed that in the hemodialysis 
population not necessarily the number of comorbidities but 
more specific comorbid conditions, like diabetes mellitus 
or peripheral vascular disease, were associated with frailty 
[4, 8, 9, 25].
Strengths of this cross-sectional study included meas-
urement of a validated construct of frailty. Due to the sin-
gle-center study of 95 participants, limitations in statistical 
power to detect small subgroup effects and generalizability 
for the dialysis population have to be taken into account. 
In contrast to the limited number of included participants, 
there was a considerable number of non-responders. This 
could lead to an underestimation of the prevalence of frailty 
in this population. Modification of physical activity, as one 
of the components of the frailty phenotype, into a self-
report single-question item could also have influenced the 
frailty phenotype prevalence estimate. By consensus, frailty 
is defined as a medical syndrome with multiple causes and 
contributors that is characterized by diminished strength, 
endurance and reduced physiologic function that increases 
an individual’s vulnerability for developing increased 
dependency and/or death. The clinical frailty scale might 
have been an alternative method for the adequate measure-
ment of this clinical syndrome [26].
In this study, frailty according to the frailty index among 
young and old ESRD patients was high. As the popula-
tion of dialysis and pre-dialysis patients is growing, frailty 
will become an important subject of clinical care. Because 
frailty is associated with poor clinical outcomes, falls, dis-
ability, hospitalization and mortality, it is important to 
identify those who are at high risk and are in need of com-
prehensive care in order to improve outcome for this vul-
nerable population [7, 15].
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